White Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial.

Pubmed ID: 33823461

Pubmed Central ID: PMC8107132

Journal: Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

Publication Date: June 1, 2021

MeSH Terms: Humans, Male, Female, Aged, Cardiovascular Diseases, Risk Factors, Middle Aged, Hypertension, Randomized Controlled Trials as Topic, Magnetic Resonance Imaging, Prognosis, Incidence, Time Factors, Predictive Value of Tests, Databases, Factual, White Matter, Leukoencephalopathies

Grants: U01 HL096812, R01 AG040282, UL1 TR001450, U24 NS107228, R01 NS082285, R01 NS086905, K23 NS105924, R01 NS084288, F32 NS010723, K24 AG052573, R18 HS027264, U01 NS087748, U01 NS080168, R18 HS025359, U24 NS107232, U19 NS115388

Authors: Gottesman RF, de Havenon A, Rost NS, Wong KH, Sheibani N, Prabhakaran S, Turan TN, Yeatts SD

Cite As: Sheibani N, Wong KH, Turan TN, Yeatts SD, Gottesman RF, Prabhakaran S, Rost NS, de Havenon A. White Matter Hyperintensity and Cardiovascular Disease Outcomes in the SPRINT MIND Trial. J Stroke Cerebrovasc Dis 2021 Jun;30(6):105764. Epub 2021 Apr 3.

Studies:

Abstract

BACKGROUND: The Systolic Blood Pressure Intervention Trial (SPRINT) randomized patients to a goal systolic blood pressure (SBP) <120 mm Hg vs. <140 mm Hg. In a subset of participants, the SPRINT MIND ancillary study performed a baseline MRI and measured white matter hyperintensity volume (WMHv). In this secondary analysis, we evaluated the association between baseline WMHv and cardiovascular events during follow-up in the overall sample. METHODS: The primary outcome was the same as SPRINT, a composite of stroke, myocardial infarction, acute coronary syndrome, decompensated congestive heart failure, or cardiovascular death. We fit Cox models to the primary outcome and report adjusted hazard ratios (HR) for log-transformed WMHv and quartiles of WMHv. RESULTS: Among 717 participants, the median (IQR) baseline WMHv was 1.62 (0.66-3.98) mL. The primary outcome occurred in 51/719 (7.1%). The median WMHv was higher in patients with the primary outcome (3.40 mL versus 1.56 mL, p < 0.001). In adjusted models, WMHv as a log-transformed continuous variable was associated with the primary outcome (HR 1.44, 95% CI 1.15-1.80). The highest quartile of WMHv, compared to the lowest, was also independently associated with the primary outcome (HR 3.21, 95% CI 1.27-8.13). CONCLUSIONS: We found that the baseline volume of WMH was associated with future CVD risk in SPRINT MIND. Prospective clinical trials with larger sample sizes than the current study are needed to determine whether intensive BP lowering can reduce the high cardiovascular risk in patients with WMH.